Identifying The Right Analytical Strategy For AAV Production: A Q&A With A CDMO Expert

Gene therapy has emerged as a powerful tool for treating a wide range of diseases, and adeno-associated virus (AAV) is a particularly promising vector for delivering these therapies. AAV's versatility in infecting various cell types makes it a frontrunner, with several FDA-approved products already showcasing its potential.

However, developing AAV therapies isn't without its hurdles. Both the manufacturing process and the analytical testing required to ensure safety and efficacy present unique challenges. Optimizing these processes is crucial for reliable production. Here's where a contract development and manufacturing organization (CDMO) with AAV expertise can be a game changer. Such a CDMO can ensure consistent, large-scale production that meets strict quality and safety regulations.